Skip to content

Startup & venture capital news

Setara Biosciences raises USD 90m Series A

Seven investors back precision medicines for rare genetic diseases

By /

LinkedInX
Setara Biosciences: Setara Biosciences raises USD 90m Series A

Setara Biosciences announced a USD 90 million Series A on 30 October 2026. Deerfield Management, Canaan, Droia Ventures, EcoR1 Capital, Euclidean Capital, Regeneron Ventures and Jazz Venture Partners joined the financing, with no lead identified. David Goldstein and David Breckenridge cofounded Setara after working together at Actio Biosciences. Setara is developing precision medicines for rare genetic diseases. Its lead programme, STAR-0871, has completed the healthy volunteer portion of a Phase 1 trial, with patient studies planned in 2027. The proceeds will support that programme and additional discovery work. The amount is current round funding, not a valuation or cumulative total.

Keep reading

More Funding

All stories